|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | N-acetylcysteine treats intravenous amiodarone induced liver injury显示文摘We report a case of intravenous(IV) amiodarone drug induced liver injury(DILI).The patient received IV N-acetylcysteine(NAC) which resulted in a rapid improvement in liver enzymes.While the specific mechanisms for the pathogenesis of IV amiodaroneDILI and the therapeutic action of IV NAC are both unknown, this case strongly implies at least some commonality.Because IV amiodarone is indicated for the treatment of serious cardiac arrhythmias in an intensive care unit setting, some degree of ischemic hepatitis is likely a cofactor in most cases. | Matthew L Mudalel Kartikeya P Dave James P Hummel Steven F Solga | 2015 | World Journal of Gastroenterology2015，21，9： | 5 |
| 2 | Breath volatile organic compounds for the gut-fatty liver axis: promise, peril, and path forward显示文摘The worldwide interest in the gut microbiome and its impact on the upstream liver highlight a critical upside to breath research: it can uniquely measure otherwise unmeasurable biology. Bacteria make gases [volatile organic compounds(VOCs)] that are directly relevant to pathophysiology of the fatty liver and associated conditions, including obesity. Measurement of these VOCs and their metabolites in the exhaled breath, therefore, present an opportunity to safely and easily evaluate, on both a personal and a population level, some of our most pressing public health threats. This is an opportunity that must be pursued. To date, however, breath analysis remains a slowly evolving field which only occasionally impacts clinical research or patient care. One major obstacle to progress is that breath analysis is inherently and emphatically mutli-disciplinary: it connects engineering, chemistry, breath mechanics, biology and medicine. Unbalanced or incomplete teams may produce inconsistent and often unsatisfactory results. A second impediment is the lack of a well-known stepwise structure for the development of non-invasive diagnostics. As a result, the breath research landscape is replete with orphaned single-center pilot studies. Often, important hypotheses and key observations have not been pursued to maturation. This paper reviews the rationale and requirements for breath VOC research applied to the gut-fatty liver axis and offers some suggestions for future development. | Steven Francis Solga | 2014 | World Journal of Gastroenterology2014，20，27： | 3 |
| 3 | Dietary Composition and Nonalcoholic Fatty Liver Disease显示文摘 | Steven Solga Amir R. Alkhuraishe Jeanne M. Clark Mike Torbenson Ashli Greenwald Anna Mae Diehl Thomas Magnuson | 2004 | Digestive Diseases and Sciences2004，，10： | 2 |
| 4 | Hepatic 31P magnetic resonance spectroscopy:a hepatologist's user guide(Review)显示文摘 | Solga SF Horska A Clark JM | 2005 | Liver Int2005，25，3： | 1 |
| 5 | Non-alcoholic fatty liver disease:lumen-liver interactions and possible role for probiotics显示文摘 | Solga SF Diehl AM | 2003 | J Hepatol2003，38，： | 1 |
| 6 | Non-alcoholic fatty liver disease:lumen -liver interactions and possible role for probiotics显示文摘 | SOLGA S F DIEHL A M | 2003 | J Hepatol2003，38，5： | 1 |
| 7 | Non-alcoholic fatty liver disease: lumenliver interactions and possible role for probioties显示文摘 | SOLGA S F DIEHL A M | 2003 | J Hepatol2003，38，5： | 1 |
| 8 | Race and comorbid factors predict nonalcoholic fatty liver disease histopathology in severely obese patients显示文摘 | Solga SF Clark JM Alkhuraishi AR | 2010 | Surg Obe s Relat Dis2010，1，： | 1 |
| 9 | The dream of staying clean: lotus and biomimetic surfaces显示文摘 | Andreas Solga Zdenek Cerman Boris F Striffler | 2007 | Bioinsp Bio mim2007，，： | 1 |
| 10 | Non - alcoholic fatty liver disease : lumenliver interactions and possible role for probiotics显示文摘 | Solga SF Diehl AM | 2003 | J Hepatol2003，38，5： | 1 |
| 11 | Can imaging modalities diagnose and stage hepatic fibrosis and cirrhosis accurately? 显示文摘 | Susanne Bonekamp Ihab Kamel Steven Solga | 2009 | Hepatology2009，50，1： | 1 |
| 12 | Breath biomarkers and non -alcoholic tarry liver disease: preliminary observations显示文摘 | Solga SF Alkhuraishe A Cope K | 2006 | Biomarkers2006，11，1： | 1 |
| 13 | Dietary compo- sition and nonalcoholic fatty lier disease 显示文摘 | Solga S Alkhuraishe A R Clark J M | 2004 | Dig Dis Sci2004，49，83： | 1 |
| 14 | The effect of a probiotic on hepatic steatosis 显示文摘 | Solga SF Buckley G Clark JM Horska A Diehl AM | 2008 | J Clin Gastroenterol2008，42，10： | 1 |
| 15 | Race and comor-bid factors predict nonalcoholic fatty liver disease histopathol-ogy in severely obese patients显示文摘 | Solga SF Clark JM Alkhuraishi AR et a1 | 2005 | Surg Obes Relat Dis2005，1，1： | 1 |
| 16 | Non-alcoholic fatty liver disease:lumenliver interactions and possible role for probiotics显示文摘 | Solga SF Diehl AM | | 0，，05： | 1 |
| 17 | Analysis of CD25hiCD4 + regu- latory T cell subtypes in atopic dermatitis reveals a novel Th2-1ike popula- tion显示文摘 | Reefer A J Satinover SM Solga MD | 2008 | J Allergy Clin Immunol2008，121，2： | 1 |
| 18 | Transformational leadership and follower's unethical behavior for the benefit of the company:A two-study investigation显示文摘 | Effelsberg D Solga M and Gurt J | 2013 | Journal of Business Ethics2013，120，1： | 1 |
| 19 | Probiotics can treat hepatic encephalopathy显示文摘 | Solga SF | 2003 | Med Hypotheses2003，61，： | 1 |
| 20 | Non-alcoholic fatty liver disease:lumen-liver interactions and possible role for probiotics显示文摘 | Solga SF Diehl AM | 2003 | Journal of Hepatology2003，38，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员